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Abstract Third-generationnonsteroidalaromataseinhibitors
(AIs),letrozoleandanastrozole,aresuperiortotamoxifenas
initial therapy for early breast cancer but have not been
directly compared in a head-to-head adjuvant trial. Cumu-
lative evidence suggests that AIs are not equivalent in terms
of potency of estrogen suppression and that there may be
differences in clinical efﬁcacy. Thus, with no data from
head-to-head comparisons of the AIs as adjuvant therapy
yet available, the question of whether there are efﬁcacy
differences between the AIs remains. To help answer this
question,theFemaraversusAnastrozoleClinicalEvaluation
(FACE) is a phase IIIb open-label, randomized, multicenter
trial designed to test whether letrozole or anastrozole has
superior efﬁcacy as adjuvant treatment of postmenopausal
women with hormone receptor (HR)- and lymph node-
positive breast cancer. Eligible patients (target accrual,
N = 4,000) are randomized to receive either letrozole
2.5 mg or anastrozole 1 mg daily for up to 5 years. The
primary objective is to compare disease-free survival at
5 years. Secondary end points include safety, overall sur-
vival, time to distant metastases, and time to contralateral
breast cancer. The FACE trial will determine whether or not
letrozole offers a greater clinical beneﬁt to postmenopausal
women with HR+ early breast cancer at increased risk of
early recurrence compared with anastrozole.
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Introduction
The aromatase inhibitors (AIs) have proven to be a pow-
erful drug class for use in hormone-sensitive breast cancer
and have shown superiority over the selective estrogen-
receptor modulator (SERM) tamoxifen in preclinical
models of hormone-dependent breast cancer [1] and in
randomized controlled trials in patients with advanced
breast cancer [2] and early breast cancer [3, 4]. Initial
adjuvant therapy with either letrozole (Femara
1) or anas-
trozole (Arimidex
1) was shown to be signiﬁcantly more
effective than tamoxifen in both the Breast International
Group (BIG) 1-98 and Anastrozole and Tamoxifen Alone
or in Combination (ATAC) randomized controlled trials in
postmenopausal women with localized breast cancer [3, 4].
In the BIG 1-98 primary core analysis, patients with
hormone receptor-positive (HR+) tumors randomized to
receive letrozole initially were compared with those
assigned to receive tamoxifen initially (N = 8,010). After a
median follow-up of 25.8 months, 351 events had occurred
in the letrozole group (n = 4,003) and 428 events in the
tamoxifen group (n = 4,007), with 5–year disease-free
survival (DFS) estimates of 84.0% and 81.4%, respec-
tively. Letrozole signiﬁcantly reduced the risk of breast
cancer recurrence (hazard ratio = 0.81; 95% conﬁdence
interval [CI] 0.70, 0.93; P = 0.003), especially the risk of
distant recurrence (hazard ratio = 0.73; 95% CI 0.60, 0.88;
P = 0.001) [3]. An analysis limited to patients randomized
to either letrozole-only or tamoxifen-only arms
(N = 4,922) was recently published and allows for more
direct comparisons with results from other trials of con-
tinuous therapy with a single endocrine agent [5]. Results
from the letrozole-only or tamoxifen-only arms were con-
sistent with those published for the primary core analysis
and showed that letrozole signiﬁcantly reduced the risk of
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P = 0.007) [5, 6] and the risk of distant metastases. After a
median follow-up of 51 months, 352 DFS events (14.3%)
were observed in the letrozole-only group (n = 2,463),
compared with 418 DFS events (16.9%) in the tamoxifen-
only group (n = 2,459) [5, 6].
The ATAC trial, which compared anastrozole with
tamoxifen for 5 years, did not have receptor positivity as a
study requirement. After a median follow-up of 68 months
(n = 6,186), anastrozole signiﬁcantly prolonged DFS (575
events with anastrozole vs. 651 events with tamoxifen;
hazard ratio = 0.87, 95% CI 0.78, 0.97; P = 0.01) and
time-to-recurrence (402 vs. 498 events; hazard ratio =
0.79, 95% CI 0.70, 0.90; P = 0.0005), and signiﬁcantly
reduced the risk of developing distant metastases (324 vs.
375 events; hazard ratio = 0.86, CI 0.74, 0.99; P = 0.04)
and contralateral breast cancers (35 vs. 59 events; 42%
reduction, 95% CI 12, 62; P = 0.01) in the intent-to-treat
(ITT) population [4]. However, neither the time to distant
recurrence nor distant DFS (DDFS) were signiﬁcantly
improved with anastrozole in the HR+ population [7].
While both letrozole and anastrozole have been evalu-
ated extensively in early breast cancer, no head-to-head
trial of these two AIs has been conducted in this setting.
This report will focus on the design of the Femara versus
Anastrozole Clinical Evaluation (FACE) trial, and describe
how it will prospectively address potential efﬁcacy and
safety differences between the two AIs.
Rationale for head-to-head trial
An American Society of Clinical Oncology technology
assessment concluded that AIs should be included in the
adjuvant treatment of postmenopausal women with HR+
breastcancer[8]butdidnotrecommendoneAIoveranother.
The National Comprehensive Cancer Network has also
recommended initial adjuvant therapy with an AI (speciﬁ-
cally letrozole or anastrozole) as an alternative to tamoxifen
[9]. Some evidence suggests that AIs may not be equivalent,
even though they belong to the same pharmacologic class of
agents; differences have been reported in terms of potency,
suppression of aromatization, antitumor effects, and phar-
macogenomics. However, whether or not one AI is superior
in treating early breast cancer is not known.
Relative potency
Bhatnagar and colleagues compared the aromatase-
inhibiting potency of letrozole and anastrozole in a variety
of aromatase-containing cellular endocrine and tumor
models [10, 11]. While letrozole and anastrozole were
approximately equipotent in a cell-free aromatase system
(human placental microsomes), letrozole was found to be
more potent than anastrozole in inhibiting intracellular
aromatase in intact rodent cells (50% inhibitory concen-
tration [IC50] 20 vs. 600 nM, respectively), normal human
adipose ﬁbroblasts (0.8 vs. 14 nM), and human cancer cell
lines (MCF-7Ca 0.07 vs. 0.82 nM and JEG-3 0.07 vs.
0.99 nM). Miller and colleagues reported that letrozole and
anastrozole were more potent than aminoglutethimide
in vitro against tumor samples obtained from postmeno-
pausal women with breast cancer, with letrozole
demonstrating the lowest IC50 (2 nM, 8 nM, and 20 lM,
respectively) [12]. Letrozole was compared with anas-
trozole in vivo in athymic mice inoculated with MCF7
cells [13]. Tumor volumes increased to 145.9% in controls
and decreased to 22.4% with letrozole 10 lg, and to 95.6%
or 78.2% with anastrozole 10 or 60 lg, respectively. These
results are consistent with a higher in vitro potency of le-
trozole in cell-based assays [13].
Suppression of aromatization
The effects of letrozole and anastrozole on suppression of
total-body aromatization and plasma estrogen concentra-
tions have been compared in patients with metastatic breast
cancer [14, 15]. Levels of aromatase were detectable in 11
of 12 patients during treatment with anastrozole (mean
percentage inhibition in the whole group, 97.3%) but in
none of the 12 patients during treatment with letrozole
([99.1% suppression in all patients; Wilcoxon,
P = 0.0022, comparing the two drug regimens). Suppres-
sion of estrone and estrone sulfate was found to be
signiﬁcantly greater during treatment with letrozole com-
pared with anastrozole (P = 0.019 and P = 0.0037,
respectively). Another study conducted in 54 postmeno-
pausal women with invasive breast cancer showed that
more complete inhibition of aromatase was achieved by
2.5 mg of letrozole than 1 mg of anastrozole, resulting in
signiﬁcantly greater suppression of estradiol (P\0.0001)
[15]. Thus, letrozole reduces estradiol levels to a greater
degree than anastrozole, but it is not known whether this
difference is clinically relevant.
Breast cancer proliferation
Biological changes in breast tumors occurring within
14 days of starting treatment may predict the efﬁcacy of
different endocrine agents in the adjuvant setting and could
prove to be useful surrogate markers to compare drug
efﬁcacy [16]. A study of neoadjuvant endocrine therapy
compared the effects of letrozole and anastrozole on the
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123expression of HRs and markers of tumor proliferation in
postmenopausal women with estrogen receptor (ER)-posi-
tive breast cancer [16]. Neoadjuvant letrozole and
anastrozole decreased overall ER expression (Allred score)
after 14 days, but more cases showed a reduction in pro-
gesterone receptor (PgR) expression following letrozole
treatment (75/106) than with anastrozole treatment (65/
102). Furthermore, only letrozole signiﬁcantly reduced
proliferation at lower Allred ER expression levels (scores
2–5). This is a potentially important ﬁnding, because it has
been suggested that a greater suppression in proliferation
may lead to improved DFS [17].
Clinical activity
Letrozole and anastrozole have not been directly compared
in the adjuvant setting, but data from a randomized, head-
to-head trial in patients with advanced breast cancer are
available [18]. Postmenopausal women with advanced
breast cancer (N = 713) that had progressed either during
antiestrogen therapy or within 12 months of completing
that therapy were randomized to receive letrozole (2.5 mg
per day) or anastrozole (1 mg per day). Letrozole was
signiﬁcantly superior to anastrozole in terms of overall
response rate (19.1% vs. 12.3%, P = 0.013), but there were
no signiﬁcant differences in median time to progression,
the primary end point of the trial. Both agents were well-
tolerated, and there were no signiﬁcant differences in
safety.
Anastrozole and letrozole in the adjuvant setting have
demonstrated superiority to tamoxifen in signiﬁcantly
reducing the risk of recurrence. In the ATAC trial, at
68 months’ median follow-up, anastrozole signiﬁcantly
reduced the risk of distant metastases in the ITT population
by 14% (P = 0.04) but not signiﬁcantly in the HR+ patient
subgroup (hazard ratio = 0.84; P = 0.06) [4]. A recent
study of the recurrence rates after 2.5 and 5 years from the
ATAC study showed that there were fewer recurrence
events with anastrozole at these time points due to reduc-
tions in contralateral, primary, loco-regional, and distant
recurrences [19]. In addition, at 25.8 months’ median fol-
low-up in the BIG 1-98 trial, letrozole signiﬁcantly reduced
the risk of distant metastases by 27% (P = 0.001) in the
HR+ population, and another analysis of the early risk of
relapse in 5,980 patients, with a median follow-up of
25 months, showed that letrozole reduced distant recur-
rences early on [3, 20]. The recently reported analysis of
letrozole-only and tamoxifen-only arms in the BIG 1-98
trial showed that the time to distant metastases advantage
for letrozole was consistent with these ﬁndings from the
primary core analysis [5]. These data are potentially
important, because the development of distant metastases
directly translates into decreased survival. The ATAC trial
showed a 3% relative improvement in overall survival (OS)
(P = 0.7) with anastrozole at 68 months of follow-up,
while a 9% relative improvement in OS (P = 0.35) was
seen with letrozole at 51 months of follow-up [3, 5].
Subset analyses of randomized trials comparing letroz-
ole or anastrozole with either tamoxifen or placebo
demonstrated differences between these AIs and suggested
that speciﬁc patient populations may derive differing
degrees of beneﬁt from a particular AI. In the trial, retro-
spective subgroup analyses with a median follow-up of
33 months revealed no signiﬁcant beneﬁt of anastrozole
over tamoxifen in patients with node-positive tumors and
with prior chemotherapy [21], and these ﬁndings were
conﬁrmed in the 4-year update of the ATAC trial. Thus, the
hazard ratio for risk of recurrence in patients with four or
more positive nodes was 0.96 (95% CI 0.72, 1.25), and in
patients with prior chemotherapy, it was 0.98 (95% CI
0.76, 1.28), indicating no differences between treatments
[22, 23]. No analyses in similar subgroups were presented
in the 68-month update [4].
Prospectively planned subgroup analysis revealed a
beneﬁt of letrozole over tamoxifen in patients who had
received chemotherapy and in those with node-positive
tumors [3, 5]. In the former subset, letrozole reduced the
risk of recurrence after 5 years (hazard ratio 0.70; 95% CI
0.54, 0.92; P = 0.01). In the node-positive subset, letrozole
reduced the risk of an event ending a period of DFS by
29% (hazard ratio 0.71, 95% CI 0.59, 0.85; P\0.001).
The advantage for letrozole in these patient subsets was
conﬁrmed in the recent analysis of the letrozole-only and
tamoxifen-only arms of BIG 1-98 [5]. Interestingly, with
longer follow-up of 51 months in this monotherapy anal-
ysis, there was an emerging beneﬁt in the node-negative
group, as letrozole reduced the relative risk of recurrence
by 12% in this patient population. The MA.17 trial, eval-
uating the efﬁcacy of extended adjuvant letrozole therapy,
although not positive for OS in the overall population,
demonstrated that OS was statistically signiﬁcantly
improved with letrozole among lymph node-positive breast
cancer patients compared with placebo (hazard ratio 0.61;
95% CI 0.38, 0.98; P = 0.04) [24].
The question of whether one third-generation AI is
superior for the adjuvant treatment of postmenopausal
women with HR+ breast cancer remains, as does the
question of whether there are any speciﬁc patient popula-
tions who derive particular beneﬁt from a speciﬁc AI.
Patients with early breast cancer can be assigned to risk
groups on the basis of clinical and pathological character-
istics. In the St. Gallen Guidelines [25], node-positive
patients are considered to be in the intermediate- or high-
risk group depending on the number of positive nodes
and human epidermal growth factor receptor-2 (HER2)
Breast Cancer Res Treat (2007) 105:67–74 69
123expression (see Table 1). The guidelines state that endo-
crine therapy with an AI is a recommended option for
patients with node-positive tumors who are in the inter-
mediate- or high-risk groups. As high-risk patients are at
greater risk of relapse, a drug speciﬁcally effective in this
patient population would provide the oncology community
with valuable information that may alter the outcomes of
these patients.
Is one AI superior in early breast cancer?
Microarray analysis was used to study the effects of vari-
ous hormone therapies on ER+ MCF-7 cells, stably
transfected with the aromatase gene (MCF-7aro cells) [26].
The study found that hormonal stimulation of gene
expression can be counteracted by treatment with AIs (le-
trozole and anastrozole) and an anti-estrogen (tamoxifen),
but that each agent had its own unique effects on gene
expression (see Fig. 1), suggesting possible differences
between letrozole and anastrozole [26]. Although differ-
ences between letrozole and anastrozole have been
demonstrated in preclinical models, it is widely recognized
that preclinical ﬁndings do not always translate into clinical
results, and that comparisons in one treatment setting or
subpopulation cannot be extrapolated to another. A pro-
spective trial is therefore needed to address the question of
whether one AI is superior to another.
FACE was designed to test whether there is a preferable
AI for the adjuvant treatment of postmenopausal women
with HR+ and lymph node-positive cancer [27]. Node-
positive patients were selected, because this population has
a higher risk of relapse, and recurrence events occur earlier
than in node-negative patients [20, 28, 29]. Thus,
conducting the FACE trial in patients with lymph node-
positive early breast cancer will provide an answer more
quickly than conducting a trial in a broader population that
includes patients with node-negative tumors.
FACE trial design
FACE is a phase IIIb open-label, randomized, multicenter
trial [30]. The primary objective of the trial is to compare
DFS at 5 years for letrozole and anastrozole. Secondary
objectives are to assess safety, OS, time to distant metas-
tases, and time to contralateral breast cancer [27].
Patients
The trial is recruiting 4,000 patients from up to 250
international sites. Eligible patients are postmenopausal
women with HR+ and lymph node-positive tumors who
have recently undergone surgery for primary breast cancer
(pathologic or clinical stage IIA, IIB, or IIIA). All patients
must provide written informed consent.
HR+ tumors are deﬁned as tumors with any detectable
ER or PgR expression by institutional standards. Patients
who are PgR+ and ER– are eligible for the trial. Pathologic
assessment of axillary lymph nodes is determined by sen-
tinel node biopsy and/or axillary lymph node dissection.
Patients are stratiﬁed according to the number of involved
lymph nodes and HER2 tumor status. Adjuvant trast-
uzumab is permitted in patients with HER2+ tumors. Other
inclusion criteria include World Health Organization per-
formance status of 0 or 1, lipid panel (fasting total
cholesterol and triglycerides) £ grade 1 (National Cancer
Table 1 Risk categories for
early breast cancer according to
the St. Gallen Guidelines.
Reprinted from [25], with
permission from the European
Society for Medical Oncology
HER2 human epithelial growth
factor receptor 2
pT pathological tumor size (i.e.
size of the invasive component)
Low risk Steroid hormone receptors expression, node-negative, and all of the following features:
pT £ 2c m
Grade 1
No peritumoral vascular invasion
HER2/neu gene neither overexpressed nor ampliﬁed
Age ‡35 years
Intermediate
risk
Node-negative and at least one of the following features:
pT[2c m
Grade 2–3
Peritumoral vascular invasion
HER2/neu gene either overexpressed or ampliﬁed
Age\35 years
Node positive (1–3 involved nodes) and HER2/neu gene neither overexpressed nor
ampliﬁed
High risk Node positive (1–3 involved nodes) and HER2/neu gene either overexpressed or
ampliﬁed
Node-positive (4 or more involved nodes)
70 Breast Cancer Res Treat (2007) 105:67–74
123Institute Common Terminology Criteria for Adverse
Events v3.0), and adequate hematologic, hepatic, and renal
function.
Patients with T4 tumors, metastatic disease, contralat-
eral breast cancer including ductal carcinoma in situ, or
evidence of disease progression are excluded. Other
exclusion criteria include prior neoadjuvant endocrine
therapy; hormone replacement therapy (except intravaginal
estradiol preparations) not stopped at least 4 weeks before
randomization; adjuvant anti-estrogen therapy for[1
month immediately following surgery, radiotherapy, and/or
chemotherapy; breast cancer chemoprevention with anti-
estrogens if\18 months between stopping and diagnosis
of breast cancer; and therapy with any hormonal agent,
such as raloxifene, for management of osteoporosis.
Randomized trial design and treatments
Eligible patients are randomized to receive either letrozole
2.5 mg or anastrozole 1 mg daily for up to 5 years (see
Fig. 2). The date of randomization must be no more than
12 weeks from completion of surgery or 4 weeks after
completion of adjuvant chemotherapy. Treatment assign-
ments are balanced based on the number of lymph nodes
(1–3, 4–9, 10+) and HER2 status (positive, negative, or
unknown). Treatment will commence within 30 days of
randomization and following the completion of standard
chemotherapy (if given) and concurrently with radiother-
apy (if given). Patients receive treatment with the allocated
AI for up to 5 years or until disease recurrence/relapse.
Recurrence and survival will be assessed every 12 months.
Efﬁcacy end points
The primary end point is DFS, deﬁned as the time from the
date of randomization to the date of the ﬁrst documentation
of re-occurrence of invasive breast cancer in local, regional,
or distant sites; new invasive breast cancer in the contra-
lateral breast; or death from any cause.
Secondary efﬁcacy end points include OS, deﬁned as the
time from the date of randomization to date of death from
any cause; breast cancer-free survival, deﬁned as the time
from date of randomization to the date of death due to
breast cancer; time to development of distant metastases,
deﬁned as the time from date of randomization to the date
of the ﬁrst development of any recurrent or metastatic
disease in sites other than the local mastectomy scar, the
ipsilateral breast in case of breast conservation, or the
contralateral breast; and time to development of contra-
lateral breast cancer, deﬁned as the time from date of
randomization to the date of the ﬁrst development of any
disease in the contralateral breast.
Although the FACE trial, co-chaired by Drs. Ian Smith
and Joyce O’Shaughnessy, is an open-label trial, analysis
of the data in a blinded fashion will make the data from this
trial comparable with that obtained in a single-blinded trial.
Both patients and their physicians will know which drug is
being taken, but the analysis of the data will be conducted
blinded to study treatment. The sponsor of the trial will not
have access to the database, and all efﬁcacy analyses will
be conducted by an independent academic organization
(the Instituto Nazionale Tumori, Milan, Italy), which will
receive the data in a blinded manner. The data will be
reviewed by an Independent Data Monitoring Committee,
chaired by Professor Martine Piccart. The Independent
Data Monitoring Committee will then make recommen-
dations to a Trial Steering Committee chaired by Dr. Kathy
Fig. 1 Changes in inhibitor-
responsive genes after treatment
with letrozole, anastrozole, or
tamoxifen. The Venn diagrams
show the numbers of genes
responsive to individual
inhibitors in hormone-regulated
genes. Reprinted from [26],
with permission from the
American Association for
Cancer Research
Fig. 2 FACE randomized trial design
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will decide when the data will be released. The ﬁnal
analysis will be performed after the expected total number
of DFS events have occurred. This is anticipated to be
7 years after the start of the study, following an accrual
period of about 2 years and a minimum of 5 years of fur-
ther follow-up. There are two planned interim analyses,
scheduled to occur after one third and subsequently after
two thirds of the maximum number of events have been
observed. The interim analyses will be conducted after 320
and 639 events, respectively, have been recorded. In
addition, analyses of secondary end points will be con-
ducted at the interim time points.
FACE is powered to detect a 3.5% absolute difference
between the two treatment arms in DFS at 5 years. The
3.5% difference corresponds to a hazard ratio of 0.83 in
favor of letrozole, corresponding to 5-year DFS values
of 80.0% and 76.5% for letrozole and anastrozole,
respectively.
Safety end points
General patient safety and drug tolerability will be evalu-
ated. Adverse events are recorded at every visit and graded
for severity using the National Cancer Institute Common
Terminology Criteria for Adverse Events v3.0. A checklist
of adverse events is used to solicit adverse event infor-
mation from patients.
Safety analyses speciﬁcally include cardiovascular
events and bone fracture events. All patients are evaluated
clinically for osteoporosis and fracture risks. Bone mineral
density testing is recommended at least every 2 years for
all patients during study therapy by dual X-ray absorpti-
ometry, peripheral dual X-ray absorptiometry, or
ultrasound densitometry. Osteoporosis may be managed as
clinically indicated using calcium supplements, vitamin D,
or bisphosphonates. Measurements of fasting serum lipids
are obtained at 6 and 12 months and then annually there-
after for the duration of the study treatment. Other
laboratory assessments include hematology and blood
chemistry.
Other head-to-head studies
Other trials that are directly comparing AIs are also under
way. A randomized phase III trial [31] is comparing neo-
adjuvant therapy with exemestane, letrozole, or anastrozole
in postmenopausal women undergoing surgery for stage II
or stage III breast cancer. Another ongoing randomized
trial, MA.27 [32], has been designed to compare the event-
free survival of postmenopausal women with HR+ primary
breast cancer when treated with exemestane or anastrozole.
Results from these trials and ongoing pharmacogenomic
studies [26] will also help individualize AI therapy for
early breast cancer.
The study of inherited genetic polymorphisms that affect
drug response and toxicity promises to help physicians
individualize hormone treatment. For example, ‘‘slow
metabolizers’’ of tamoxifen may have a worse outcome in
the adjuvant setting with tamoxifen treatment than ‘‘fast
metabolizers,’’ suggesting that these patients might be
better treated with an AI [33–35]. Polymorphisms in
tamoxifen metabolizing cytochrome P (CYP) 2D6 gene
affect the plasma concentration of tamoxifen active
metabolites: women with the CYP2D6 *4/*4 or wt/*4
genotype could have lower beneﬁt of tamoxifen treatment
and tend to have a higher risk of disease relapse [35, 36].
Genetic polymorphisms in the aromatase gene, CYP19,
have recently been characterized [37]. Eighty-eight poly-
morphisms were identiﬁed, resulting in 44 haplotypes.
Functional genomic studies revealed that polymorphisms
may lead to changes in aromatase activity and altered
afﬁnity for AIs. These ﬁndings indicate that genetic vari-
ation in CYP19 might contribute to variation in the
pathophysiology of estrogen-dependent disease. Clinical
trials have been initiated to study the impact of genetic
differences on response to AI therapy and may eventually
lead to patient-speciﬁc selection of therapy based on opti-
mizing efﬁcacy and toxicity.
Conclusions
Letrozole and anastrozole have both demonstrated superior
efﬁcacy compared with tamoxifen as initial therapy for
early breast cancer [3, 4]. Preclinical and clinical evidence
suggests that AIs do not have identical pharmacodynamic
proﬁles, but it is not known whether one agent may be
more effective as adjuvant therapy for early breast cancer.
Differences in potency in preclinical studies, and the
reduction in distant metastases in the BIG 1-98 study,
suggest the potential for clinical efﬁcacy differences
between AIs. Based on the results of these trials, interna-
tional guidelines now recommend adjuvant hormone
therapy with an AI [9, 25] in patients with an increased risk
of early recurrence. The FACE trial is addressing an
important medical question in the oncology community:
whether or not letrozole offers greater clinical beneﬁt to
postmenopausal women with HR+ early breast cancer at
increased risk of early recurrence compared with anas-
trozole. Results from the FACE trial may reﬁne the
treatment strategies for treating breast cancer in postmen-
opausal women.
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